[ET Net News Agency, 30 April 2021] CanSino Biologics Inc. (06185) said its net loss
attributable to shareholders of the listed company was RMB14.11 million for the first
quarter of 2021, compared to the loss of RMB23.10 million of the same period last year.
Basic loss per share was RMB0.06.
Operating revenue was RMB466.76 million, a year-on-year increase of 11483.21%. (RC)